24/7 Market News Snapshot 13 February, 2025 – Nutriband Inc. Common Stock (NASDAQ:NTRB)

February 13, 2025

DENVER, Colo., 13 February, 2025 (247marketnews.com) – (NASDAQ:NTRB) are discussed in this article.
Nutriband Inc. has experienced significant volatility in its stock performance, opening at $8.00 and currently trading at $7.86, reflecting a decline of approximately 10.39%. The stock closed the previous session at $7.12, indicating a potential reversal of momentum and prompting interest in the stock’s support and resistance levels. With trading volume reaching 649.62K, investor attention appears heightened, likely influenced by recent developments surrounding the company. Market participants are advised to exercise caution amidst the current price fluctuations while keeping an eye on technical indicators such as the Relative Strength Index (RSI) to inform short-term trading strategies.

Concurrently, Nutriband has reinforced its product development initiatives through a strategic partnership with Kindeva Drug Delivery, having signed an addendum to their existing Commercial Development and Clinical Supply Agreement. This collaboration focuses on the advancement of Aversa™ Fentanyl, a cutting-edge solution aiming to combat the escalating concerns of opioid abuse. The partnership is poised to leverage Nutriband’s proprietary Aversa™ abuse-deterrent technology, which integrates aversive agents into transdermal patches, thus mitigating the risks associated with misuse, abuse, and accidental exposure.

As the world’s first abuse-deterrent opioid patch, Aversa™ Fentanyl is seen as a vital innovation that balances patient access with enhanced safety measures. This development is projected to substantially impact the market, with anticipated U.S. sales ranging from $80 million to $200 million annually. By sharing development costs and solidifying milestone payment structures, Nutriband and Kindeva are committed to expediting the commercialization of this essential product. Together, they aspire to lead in creating safer pharmaceutical solutions that address pressing public health challenges associated with opioid misuse and abuse, highlighting Nutriband’s role in advancing pharmaceutical innovation.

Related news for (NTRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.